Extended Data Table 1 Additional safety and tolerability of FX-909 - patients with dose interruptions, dose reductions, and DLTs

From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial

  1. *Dose interruptions & reductions: 3 pts were excluded from the summary and 1 pt was ongoing and hasn’t completed 56 days of dosing at the date of data cut off.
Back to article page